🔴 Abcellera Biologics is trading 8.61% down in pre-market after announcing a proposed $200 million public offering

Abcellera Biologics is trading 8.61% down at $8.92 in pre-market after announcing a proposed $200 million underwritten public offering.

• The financing includes common shares and pre-funded warrants, creating potential dilution following the stock’s sharp rally after positive ABCL635 Phase 2 results.
• Proceeds are intended to fund pipeline research, clinical development, working capital, and general corporate purposes.
• Pricing and share-count details were not disclosed; the announcement was made on August 11, 2026.